Overview

MT1002 Phase II Study in ACS Patients With PCI

Status:
Active, not recruiting

Trial end date:
2021-10-01

Target enrollment:

Participant gender:

Summary

This is an open-label, sequential-dose escalation/de-escalation trial testing 3 dose levels of MT1002 in patients undergoing PCI due to ACS with NSTEMI.

Phase:

Phase 2

Details

Lead Sponsor:

Shaanxi Micot Technology Limited Company